Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1993 Jul 1;90(13):5924–5928. doi: 10.1073/pnas.90.13.5924

chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects.

I Asplin 1, G Galasko 1, J Larner 1
PMCID: PMC46839  PMID: 8392181

Abstract

chiro- and myo-Inositols are major components of the two inositol phosphoglycan mediators of insulin action. Previous work in this laboratory has shown hypo-chiro-inositoluria in type II diabetic subjects and decreased chiro-inositol in mediator prepared from skeletal-muscle biopsies of Pima Indian diabetic subjects together with increased myo-inositol concentrations. Because mediator bioactivity was not previously examined, we decided to isolate the two types of insulin mediator from hemodialysate, urine, and autopsy muscle to investigate their bioactivity in control and type II diabetic subjects. Human mediator fractions were isolated at pH 2.0 and pH 1.3 from hemodialysate, urine, and autopsy muscle of type II diabetic subjects and nondiabetic control subjects. Mediators were assayed for bioactivity, and the relative chiro-inositol/myo-inositol concentration ratio was determined for the mediator pH 2.0 samples by using HPLC or GC/MS. Regardless of source, the chiro-inositol-containing mediator pH 2.0 fractions from type II diabetic subjects were markedly less active than those from controls (50% or less) (P < 0.05). In addition, the chiro-inositol/myo-inositol ratio in samples from type II subjects was significantly reduced (1/3-1/9) compared with controls (P < 0.05 for hemodialysate and P < 0.01 for muscle samples). In contrast, no difference in bioactivity was seen in myo-inositol-containing mediator pH 1.3 samples isolated from the same type II diabetic and control subjects. In type II diabetes there is a generalized deficiency of chiro-inositol mediator in the body in terms of both decreased chiro-inositol mediator (pH 2.0) bioactivity and chiro-inositol content.

Full text

PDF
5924

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beck-Nielsen H., Vaag A., Damsbo P., Handberg A., Nielsen O. H., Henriksen J. E., Thye-Rønn P. Insulin resistance in skeletal muscles in patients with NIDDM. Diabetes Care. 1992 Mar;15(3):418–429. doi: 10.2337/diacare.15.3.418. [DOI] [PubMed] [Google Scholar]
  2. Cheng K., Galasko G., Huang L., Kellogg J., Larner J. Studies on the insulin mediator. II. Separation of two antagonistic biologically active materials from fraction II. Diabetes. 1980 Aug;29(8):659–661. doi: 10.2337/diab.29.8.659. [DOI] [PubMed] [Google Scholar]
  3. DeFronzo R. A., Bonadonna R. C., Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992 Mar;15(3):318–368. doi: 10.2337/diacare.15.3.318. [DOI] [PubMed] [Google Scholar]
  4. Kennington A. S., Hill C. R., Craig J., Bogardus C., Raz I., Ortmeyer H. K., Hansen B. C., Romero G., Larner J. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1990 Aug 9;323(6):373–378. doi: 10.1056/NEJM199008093230603. [DOI] [PubMed] [Google Scholar]
  5. Larner J., Galasko G., Cheng K., DePaoli-Roach A. A., Huang L., Daggy P., Kellogg J. Generation by insulin of a chemical mediator that controls protein phosphorylation and dephosphorylation. Science. 1979 Dec 21;206(4425):1408–1410. doi: 10.1126/science.228395. [DOI] [PubMed] [Google Scholar]
  6. Larner J., Huang L. C., Schwartz C. F., Oswald A. S., Shen T. Y., Kinter M., Tang G. Z., Zeller K. Rat liver insulin mediator which stimulates pyruvate dehydrogenase phosphate contains galactosamine and D-chiroinositol. Biochem Biophys Res Commun. 1988 Mar 30;151(3):1416–1426. doi: 10.1016/s0006-291x(88)80520-5. [DOI] [PubMed] [Google Scholar]
  7. Larner J., Huang L. C., Tang G., Suzuki S., Schwartz C. F., Romero G., Roulidis Z., Zeller K., Shen T. Y., Oswald A. S. Insulin mediators: structure and formation. Cold Spring Harb Symp Quant Biol. 1988;53(Pt 2):965–971. doi: 10.1101/sqb.1988.053.01.111. [DOI] [PubMed] [Google Scholar]
  8. Lilley K., Zhang C., Villar-Palasi C., Larner J., Huang L. Insulin mediator stimulation of pyruvate dehydrogenase phosphatases. Arch Biochem Biophys. 1992 Jul;296(1):170–174. doi: 10.1016/0003-9861(92)90559-f. [DOI] [PubMed] [Google Scholar]
  9. Lillioja S., Mott D. M., Zawadzki J. K., Young A. A., Abbott W. G., Knowler W. C., Bennett P. H., Moll P., Bogardus C. In vivo insulin action is familial characteristic in nondiabetic Pima Indians. Diabetes. 1987 Nov;36(11):1329–1335. doi: 10.2337/diab.36.11.1329. [DOI] [PubMed] [Google Scholar]
  10. McCaleb M. L., Mevorach R., Freeman R. B., Izzo M. S., Lockwood D. H. Induction of insulin resistance in normal adipose tissue by uremic human serum. Kidney Int. 1984 Feb;25(2):416–421. doi: 10.1038/ki.1984.33. [DOI] [PubMed] [Google Scholar]
  11. Nestler J. E., Romero G., Huang L. C., Zhang C. G., Larner J. Insulin mediators are the signal transduction system responsible for insulin's actions on human placental steroidogenesis. Endocrinology. 1991 Dec;129(6):2951–2956. doi: 10.1210/endo-129-6-2951. [DOI] [PubMed] [Google Scholar]
  12. Ortmeyer H. K., Bodkin N. L., Lilley K., Larner J., Hansen B. C. Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys. Endocrinology. 1993 Feb;132(2):640–645. doi: 10.1210/endo.132.2.8425483. [DOI] [PubMed] [Google Scholar]
  13. Pak Y., Huang L. C., Lilley K. J., Larner J. In vivo conversion of [3H]myoinositol to [3H]chiroinositol in rat tissues. J Biol Chem. 1992 Aug 25;267(24):16904–16910. [PubMed] [Google Scholar]
  14. Pak Y., Larner J. Identification and characterization of chiroinositol-containing phospholipids from bovine liver. Biochem Biophys Res Commun. 1992 Apr 30;184(2):1042–1047. doi: 10.1016/0006-291x(92)90696-i. [DOI] [PubMed] [Google Scholar]
  15. Portha B., Serradas P., Bailbé D., Suzuki K., Goto Y., Giroix M. H. Beta-cell insensitivity to glucose in the GK rat, a spontaneous nonobese model for type II diabetes. Diabetes. 1991 Apr;40(4):486–491. doi: 10.2337/diab.40.4.486. [DOI] [PubMed] [Google Scholar]
  16. Rothman D. L., Shulman R. G., Shulman G. I. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. J Clin Invest. 1992 Apr;89(4):1069–1075. doi: 10.1172/JCI115686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Saltiel A. R., Siegel M. I., Jacobs S., Cuatrecasas P. Putative mediators of insulin action: regulation of pyruvate dehydrogenase and adenylate cyclase activities. Proc Natl Acad Sci U S A. 1982 Jun;79(11):3513–3517. doi: 10.1073/pnas.79.11.3513. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES